Shockwave Medical Inc (OQ:SWAV)

Oct 22, 2020 04:05 pm ET
Shockwave Medical Announces VIVA20 Investor Update and Conference Call Discussing Third Quarter 2020 Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease will webcast an investor update at the virtual VIVA20 on Saturday,...
Oct 20, 2020 08:00 am ET
Shockwave Disrupt PAD III Results to be Presented in Late-Breaking Session at VIVA20
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the acute results from the DISRUPT PAD III...
Oct 15, 2020 12:35 pm ET
Shockwave IVL Meets Safety and Effectiveness Endpoints in U.S. Coronary Pivotal IDE Study
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the coronary Investigational Device Exemption...
Oct 01, 2020 08:00 am ET
Shockwave Announces Updated Time for CAD III Investor Webcast Event in Conjunction with TCT Connect
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced updated timing for the company’s CAD III Investor...
Sep 15, 2020 08:00 am ET
Shockwave Coronary IVL U.S. Pivotal Study Results to be Presented in Late-Breaking Session at TCT Connect
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the pivotal results from the  DISRUPT CAD III...
Aug 26, 2020 08:00 am ET
Shockwave Medical to Participate in Upcoming September Investor Conferences
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Shockwave management is scheduled to speak at the following upcoming...
Aug 11, 2020 04:05 pm ET
Shockwave Medical Reports Second Quarter 2020 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30,...
Jul 30, 2020 08:00 am ET
Shockwave Medical to Present at the Canaccord Genuity 40th Annual Growth Conference
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth...
Jul 21, 2020 04:05 pm ET
Shockwave Medical to Report Second Quarter 2020 Financial Results on August 11, 2020
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter...
Jul 20, 2020 08:00 am ET
Shockwave Appoints Maria Sainz to Board of Directors
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors and will serve on...
Jul 08, 2020 04:33 pm ET
Shockwave Announces Decisions From the U.S. Patent and Trademark Office on Inter Partes Review Proceeding
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company received the initial rulings related to two of the inter...
Jun 16, 2020 08:20 pm ET
Shockwave Announces Pricing of Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 1,700,000 shares of its common stock at a price to the public of $45.75 per share. All of the shares are being offered by Shockwave. The...
Jun 16, 2020 07:39 am ET
Shockwave Announces Proposed Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of 1,700,000 shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition, Shockwave...
Jun 08, 2020 04:30 pm ET
Shockwave Medical Announces That CMS Has Created New Codes for Intravascular Lithotripsy
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Centers for Medicare & Medicaid Services (CMS)...
May 12, 2020 04:03 pm ET
Shockwave Medical Reports First Quarter 2020 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
Apr 30, 2020 08:00 am ET
Shockwave Medical to Present at the Bank of America Securities 2020 Health Care Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced today that the company will be participating in the upcoming Bank of America...
Apr 21, 2020 04:05 pm ET
Shockwave Medical to Report First Quarter 2020 Financial Results on May 12, 2020
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter...
Apr 13, 2020 08:00 am ET
Shockwave Completes Enrollment of Coronary Intravascular Lithotripsy Study in Japan
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company has completed enrollment in their DISRUPT CAD IV study of...
Apr 06, 2020 08:00 am ET
SHOCKWAVE COMPLETES ENROLLMENT IN PIVOTAL STUDY FOR CORONARY INTRAVASCULAR LITHOTRIPSY
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has completed enrollment in the...
Feb 13, 2020 04:03 pm ET
Shockwave Medical Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Financial Outlook
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year...
Jan 21, 2020 04:05 pm ET
Shockwave Medical to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the fourth quarter...
Nov 14, 2019 10:00 pm ET
Shockwave Announces Pricing of Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced the pricing of its public offering of 2,481,781 shares of its common stock at a price to the public of $36.25 per share. All of the shares are being offered by Shockwave. The...
Nov 12, 2019 04:13 pm ET
Shockwave Announces Proposed Public Offering of Common Stock
Shockwave Medical, Inc. (“Shockwave”) (Nasdaq: SWAV) today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of common stock are being offered by Shockwave. In addition,...
Nov 08, 2019 08:30 am ET
Shockwave Medical to Participate in the 13th Annual Canaccord Genuity Medical Technologies & Diagnostics Forum
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat with...
Nov 07, 2019 04:03 pm ET
Shockwave Medical Reports Third Quarter 2019 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September...
Nov 07, 2019 08:30 am ET
Shockwave Initiates Study of Coronary Intravascular Lithotripsy in Japan
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company has initiated the DISRUPT CAD IV study of IVL in heavily...
Nov 04, 2019 08:30 am ET
Shockwave Announces Commercial Availability of Below-the-Knee IVL Catheter
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced commercial availability of the Shockwave S4 Peripheral IVL Catheter in select...
Oct 17, 2019 04:03 pm ET
Shockwave Medical to Report Third Quarter 2019 Financial Results on November 7, 2019
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter...
Sep 25, 2019 11:00 am ET
Shockwave Study Demonstrates Strong Safety and Procedural Success of Coronary IVL in Europe
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, unveiled the results of the DISRUPT CAD II study, a European post-market study of coronary...
Sep 03, 2019 08:30 am ET
Shockwave Receives FDA Breakthrough Device Designation for the Coronary IVL System
Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced that the company has received Breakthrough Device Designation from the...
Aug 21, 2019 08:30 am ET
Shockwave Medical to Participate in Upcoming Investor Conferences
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will be participating in two upcoming...
Aug 05, 2019 04:03 pm ET
Shockwave Medical Reports Second Quarter 2019 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30,...
Jul 23, 2019 04:03 pm ET
Shockwave Medical to Participate in the 39th Annual Canaccord Genuity Global Growth Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will participate in a fireside chat with...
Jul 23, 2019 04:03 pm ET
Shockwave Medical to Report Second Quarter 2019 Financial Results on August 5, 2019
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the second quarter...
Jun 10, 2019 08:00 am ET
Shockwave Appoints Hajime Tada as General Counsel
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Hajime Tada as General...
May 15, 2019 08:00 am ET
Shockwave Appoints Keith D. Dawkins M.D. as Chief Medical Officer
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the Company has appointed Keith D. Dawkins, M.D....
May 08, 2019 04:03 pm ET
Shockwave Medical Reports First Quarter 2019 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31,...
May 01, 2019 08:30 am ET
Shockwave Medical to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced the company will be participating in the upcoming Bank...
Apr 24, 2019 08:30 am ET
Shockwave Medical to Report First Quarter 2019 Financial Results on May 8, 2019
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the first quarter...
Apr 03, 2019 08:00 am ET
Shockwave Completes Enrollment of Disrupt CAD II Study
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, has completed enrollment of its DISRUPT CAD II study, a...
Mar 11, 2019 04:10 pm ET
ShockWave Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ShockWave Medical, Inc. (“ShockWave”) (Nasdaq: SWAV), today announced the closing of its initial public offering of 6,555,000 shares of its common stock at an initial public offering price of $17.00 per share, including 855,000 shares sold pursuant...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.